Evaluation of Drug and Vaccine Candidates in the Human Malaria/Aotus Monkey Model
Annual rept. 1 Mar 97-28 Feb 98
PROMED TRADING S A MIAMI FL
Pagination or Media Count:
The Plasmodium falciparum 1088 strain did not adapt in Aotus Iemurinus Iemurinus when inoculated intraperitoneally. A Salvador I strain of Plasmodium vivax was adapted to splenectomized and intact Aotus after serial passage. Artelinic acid WR255663AK JN8331 when given to Aotus by the oral route at 20 mgkg b.i.d. for three days, appeared to be safe, and cleared a P. falciparum FVO infection. Re-treatment at 40 mgkg cured a recrudecence that occurred 31 days PI. In vaccine studies, neither, Aotus immunized intradermally ID with AMA-1, EBA-175 and MSP-1 plasmid DNA vaccines alone or in combination, nor, Aotus immunized ID with AMA-1, EBA-175 and MSP-1 plasmid DNA vaccines as a combination with or without aGM-CSF, were protected against a challenge with an FVO strain of P. falciparum. However, when AMA-1, EBA-175 and MSP-1 plasmid DNA vaccines were given ID as a combination to P. falciparum FVO cured Aotus, 416 67 animals were protected against an homologous infection. Total absence of antibody responses were observed in Aotus after three ID immunizations with P. vivax DNA vaccines based on PvCSP, PvSSP2, PvMSP-1 p42, PvAMA1, and PvDBPregions II-IV alone or in combination. Homologous re-challenge with Vietnam-Oak Knoll parasites resulted in thirteen Aotus with sterile immunity after 4-6 inoculations.
- Medicine and Medical Research